New drug treatments for cystic fibrosis
Abstract
Patients are finally seeing the benefits after a long and agonising waitKeywords
This publication has 12 references indexed in Scilit:
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleNew England Journal of Medicine, 2019
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesNew England Journal of Medicine, 2018
- VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesNew England Journal of Medicine, 2018
- Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic FibrosisNew England Journal of Medicine, 2017
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delNew England Journal of Medicine, 2017
- Academic, Foundation, and Industry Collaboration in Finding New TherapiesNew England Journal of Medicine, 2017
- Precision Medicine: At What Price?American Journal of Respiratory and Critical Care Medicine, 2015
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011